Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients

Trial Profile

A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARO-ANG3 (Primary)
  • Indications Dyslipidaemias; Hyperlipoproteinaemia type IIa; Hypertriglyceridaemia; Non-alcoholic fatty liver disease
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 18 Nov 2019 Results published in the Arrowhead Pharmaceuticals Media Release.
    • 18 Nov 2019 According to an Arrowhead Pharmaceuticals Media Release, data from this study were presented at the American Heart Association (AHA) Scientific Sessions 2019.
    • 18 Oct 2019 According to an Arrowhead Pharmaceuticals Media Release, phase 1 data of ARO-ANG3 will be presented on November 18, 2019, in the Late Breaking Science VI: New Frontiers in Lipid Therapy session at the American Heart Association meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top